Clinical characteristics of 3 patients with FLT3-ITD mutations, treated with FLT3 inhibitors, who subsequently developed tender skin nodular consisting of FLT3-mutant infiltrating neutrophilic infiltrates
| Patient . | Age/sex . | WBC (/µL) at presentation . | WBC (/µL) (neutrophil, blast %) at time of skin lesion . | Karyotype . | FLT3 status . | NPM1 status . | FLT3 Inhibitor . | Time to onset of skin lesion, wk . |
|---|---|---|---|---|---|---|---|---|
| 1 | 29/female | 30 000 | 550 (4%, 0%) | Normal | ITD | Mutant | Quizartinib | 8 |
| 2 | 60/female | 40 000 | 570 (76%, 0%) | t (10;17), del (15) | ITD | Mutant | Quizartinib | 6 |
| 3 | 56/male | 6600 | 1100 (56%, 8%) | del (7q) | ITD | WT | Sorafenib | 2 |
| Patient . | Age/sex . | WBC (/µL) at presentation . | WBC (/µL) (neutrophil, blast %) at time of skin lesion . | Karyotype . | FLT3 status . | NPM1 status . | FLT3 Inhibitor . | Time to onset of skin lesion, wk . |
|---|---|---|---|---|---|---|---|---|
| 1 | 29/female | 30 000 | 550 (4%, 0%) | Normal | ITD | Mutant | Quizartinib | 8 |
| 2 | 60/female | 40 000 | 570 (76%, 0%) | t (10;17), del (15) | ITD | Mutant | Quizartinib | 6 |
| 3 | 56/male | 6600 | 1100 (56%, 8%) | del (7q) | ITD | WT | Sorafenib | 2 |
WT, wild-type.